1. Home
  2. NVO

as of 11-06-2026 3:49pm EST

$40.25
+$0.07
+0.17%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Founded: 1923 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 199.4B IPO Year: 2001
Target Price: $45.11 AVG Volume (30 days): 8.7M
Analyst Decision: Hold Number of Analysts: 14
Dividend Yield:
3.18%
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $35.12 - $64.16 Next Earning Date: 11-04-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -1.74% Revenue Growth (next year): 1.30%
P/E Ratio: 13.60 Index: N/A
Free Cash Flow: N/A FCF Growth: +6.58%

Share on Social Networks: